HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
HERON THERAPEUTICS, INC. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.36−0.00 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $68.69M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.9291 (−72.02%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
HERON THERAPEUTICS, INC. /DE/ grew revenue 1.0% to $151.18M over the twelve months to Jun 30, 2026. Operating income fell 981.8% to -$10.86M, moving the operating margin from 0.8% to -7.2%. Free cash flow was -$12.14M.
Revenue
$151.18M
+1.0% vs. a year earlier
Operating income
-$10.86M
-981.8% vs. a year earlier
Free cash flow
-$12.14M
TTM Q2 2026
EPS, diluted
-$0.19
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $68.69M
- P/E ratio
- –
- Price to sales
- 0.45
- Price to book
- 9.94
- Dividend yield
- –
- Free cash flow yield
- -17.67%
Fundamentals
- Revenue
- $151.18M
- Net income
- -$34.05M
- EPS, diluted
- -$0.19
- Free cash flow
- -$12.14M
- Book value per share
- $0.04
- Diluted shares
- 190M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$151.18M+1.0% YoY
Gross profit
$105.94M-5.2% YoY
Operating income
-$10.86M-981.8% YoY
Net income
-$34.05M
EPS, diluted
-$0.19
Free cash flow
-$12.14M
Reported periodTrailing twelve months